R & D projects (Q3312831): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Changed an Item: Edited by the beneficiary bot - attach the beneficiary based on the string) |
||
| Property / beneficiary | |||
| Property / beneficiary: Q3383143 / rank | |||
Normal rank | |||
Revision as of 17:40, 26 October 2021
Project Q3312831 in Germany
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | R & D projects |
Project Q3312831 in Germany |
Statements
516,561.12 Euro
0 references
1,067,495.6 Euro
0 references
48.39 percent
0 references
17 March 2020
0 references
31 March 2022
0 references
HWI pharma services GmbH
0 references
49°13'20.17"N, 8°21'59.72"E
0 references
76761
0 references
Mit der innovativen Screening- und Technologie-Plattform lassen sich parenterale (sterile) Arzneimittel mit schwerlöslichen chemischen und biologischen Wirkstoffen mittels Nanotechnologie schneller, effizienter und kostengünstiger entwickeln und herstellen. (German)
0 references
With the innovative screening and technology platform, parenteral (sterile) medicines with insoluble chemical and biological agents can be developed and manufactured using nanotechnology faster, more efficiently and cost-effectively. (English)
25 October 2021
0 references
Germersheim
0 references
Identifiers
DE_TEMPORARY_15618
0 references